{"description":"For patients in Arm A, adverse events (of any grade) considered possibly, probably, or definitely related to the MLA need be reported. Adverse events that are possibly, probably, or definitely related to study procedures will be followed until resolution or stabilization of the event. \"Stabilization\" is defined as remaining at a consistent CTCAE version 4.0 grade of the event for two consecutive assessments. For Arm B, all grade 3 and higher events regardless of attribution are to be reported.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"EG000","otherNumAffected":5,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Arm A (MRI-guided Laser Ablation)"},{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m\\^2 over 5-30 minutes\n* Following the completion of doxorubin, etoposide 50 mg/m\\^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first","id":"EG001","otherNumAffected":0,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"Arm B (MRI-guided Laser Ablation, Doxorubicin, Etoposide)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Fecal incontinence"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Paresthesia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Memory impairment"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Confusion"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Social circumstances","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Noise sensitive"}],"timeFrame":"-Reportable adverse events will be tracked for 30 days following the last day of study treatment for patients in Arm B and for 30 days following the MLA for patients in Arm A. -All-cause mortality will be collected from start of treatment up to 5 years after start of treatment (median length of follow-up 413.5 days, full range 366 days-1801 days)."}